Sickle Cell DiseaseSIMCS SCDNCT06563440
Development and Evaluation of an Information Management System and Communication System for Population-wide Point-of-care Infant Sickle Cell Disease Screening
A study testing Digital app and information system in people with Sickle Cell Disease, run by Makerere University at 2 sites in 2 countries.
Trial summary
Although over 75% of children with sickle cell disease (SCD) are born in sub-Sahara where the disease highly contributes to under-5 mortality and causes life-long debilitation, evidence-based strategies to control SCD are not widely implemented in this region. Read more about this study
- Who is it for?
- Ages Up to 5 yearsHealthy volunteers can take part
- Conditions the study is for
- Sickle Cell Disease
- What is being tested?
- Digital app and information system
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24,000 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 21 Aug 2024to 31 Jul 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 5 years
- All sexes
- Healthy volunteers accepted
- Child
Inclusion Criteria: A participant will be eligible for enrolment if at baseline they are an infant less than 1 year of age and presents to any of the health centers in the communities where the project will be conducted.
Exclusion Criteria: Persons 1 year or older
Trial locations and contacts
2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
2 sites in 2 countries
Uganda1 site
College of Health Sciences, Makerere University
Kampala, 256
Nelson K Sewankambo, MBChB, +256782366751, sewankam@infocom.co.ug
Harriet Nambooze, +256777504301, harrietnambooze@gmail.com
About this study
Although over 75% of children with sickle cell disease (SCD) are born in sub-Sahara where the disease highly contributes to under-5 mortality and causes life-long debilitation, evidence-based strategies to control SCD are not widely implemented in this region. Early detection of SCD by universal infant screening is a pillar of SCD control. Despite the affordability and move to adopt point-of-care (POC) SCD screening assays in sub-Sahara Africa, the absence of screening information management and communication systems (SIMCS) impedes standardized, systematic, coordinated, nationwide SCD screening programs. The long-term goal of the proposed research is to develop a SCD SIMCS that will enable universal SCD screening in the sub-Sahara African setting. The objective is to test and optimize a custom SCD SIMCS app and digital network to facilitate SCD screening and then evaluate its impact on access to SCD screening and care and on clinical outcomes of children with SCD in Uganda. The central hypothesis is that the SCD SIMCS will facilitate accurate and coordinated POC SCD screening that is accessible at health centers in urban and rural Uganda. The rationale is to build a custom SCD SIMCS on existing nationwide digital and health infrastructure in Uganda to standardize use of affordable POC assays at health centers nationwide. The central hypothesis will be tested by pursuing two specific aims: 1) Develop and evaluate a four-module ≥3G cell phone app for a novel SCD SIMCS (R21 Phase); 2) Evaluate the impact of the SCD SIMCS on access to screening and care and outcomes of children with SCD (R33 Phase). The investigators will pursue these aims using an innovative combination of software design and re-organization of SCD screening workflows. These include assembly of off-the-shelf software that is compatible with iOS and Android operating systems to reliably, accurately, and handily capture, interpret, transmit, and retrieve/playback information for patient's IDs, test results, salient clinical events, and education. The novel screening workflows are expected to dramatically reduce the cost and increase access to SCD screening and care. The proposed research is significant, because it will determine how to use POC SCD screening assays on a large nationwide scale. It will also enable coordination of evidence-based care and continuity of care between primary and specialist providers and longitudinally over the patient's lifetime - a critical aspect in controlling this life-long disease. The SCD SIMCS will also facilitate real time data management for research and policy for SCD control. The expected immediate outcome of this research is a SCD SIMCS that optimally functions on the digital and health infrastructure in Uganda and demonstration of its impact on access to SCD screening and care and on clinical outcomes of children with SCD. The expected long-term outcome is that the SCD SIMCS will be adopted, integrated, and scaled-up in the health systems of Uganda and other sub-Sahara Africa countries, particularly those where the POC assays have already been adopted as the national standard of SCD screening. If effective, the SCD SIMCS will have an important positive impact because it will reduce the cost of SCD screening, take screening services and evidence-based care closer to rural communities where the majority of children in sub-Sahara Africa live, and, ultimately, save millions of children from preventable and disability death.
Read the detailed description
This trial builds on our multidisciplinary experience in pediatric sickle cell disease (SCD) care, mHealth platforms, and community-based research in Uganda to develop, validate, and trial a novel SCD screening information management and communication system (SCD SIMCS) that enables community-wide point-of-care (POC) SCD screening and care coordination. The SCD SIMCS network will be built on existing population-wide digital infrastructure and a Tier2 data center at the Uganda Ministry of Health (MOH) hub. The network will consist of 3 components: (1) ≥2G cell phone (patients) for short message service (SMS); (2) ≥3G cell phone (providers) for a custom Application (App) that facilitates SCD testing, patient education, and care coordination; (3) Tier2 data center (MOH hub) to receive, curate and transmit data and information in the SCD SIMCS network. The network will involve families, primary care providers (PCP), pediatric hematology specialists, and a national MOH hub for SCD screening. The purpose is to improve outcomes of children with SCD through early detection and linkage into care.
SCD is a group of inherited chronic red blood cell (RBC) disorders characterized by chronic hemolytic anemia, pain crises, and end-organ damage. SCD affects about 15 million individuals in SSA, and about 340,000 children are born with the disease annually. Only 10% of these children reach adolescence in SSA compared to almost 90% of patients that reach adulthood in high-income countries.3 Although SCD contributes about 16% of under-5 mortality in SSA, it is under-recognized because most children die of the disease without a diagnosis.
Early detection through screening is the foremost strategy in reducing SCD morbidity and mortality because it is a pre-requisite for prevention of complications using interventions such as hydroxyurea, vaccination, and health education.24 Whereas several assays for SCD screening exist, attempts to introduce them in SSA at a large scale have been futile because of the unaffordable logistics and complex workflows involved in traditional designs of infant screening programs. Transportation of samples and maintenance of sample-patient ID, transmission of test results to families and providers, pre- and post-screening counseling, referral for treatment for those diagnosed with SCD, and program evaluation are all critical steps in screening and are dependent on affordability, reliability, and integrity of information transfer between the stakeholders at each step. The investigators hypothesize that the SCD SIMCS will bridge these gaps in the screening process in Uganda and sustainably improve outcomes of children with SCD. The investigators propose the following Specific Aims to develop, validate, and trial a sustainable and error-proof mHealth system that will subsequently be adoptable and sustainable to facilitate population-wide SCD screening in Uganda:
Aim 1. To develop and evaluate a four-module ≥3G cell phone app for a novel SCD screening information management and communication system (SIMCS) (R21 Phase). The App will capture and interpret POC assays, capture and maintain a high-fidelity patient ID system, serve as a SCD e-passport interface, and facilitate SCD pre- and post- test counseling. The investigators will iteratively test the feasibility, accuracy, reproducibility, efficacy and robustness of the custom App and SCD SIMCS in our Mulago National Referral Hospital (MNRH)/Makerere University College of Health Sciences (MakCHS) Sickle Cell Program and affiliated primary health centers in Kampala. The goal is to enable a simple, error-free, reliable, and standardized SCD screening using a low-cost POC assay that can be performed across wide ranging health center levels and health worker expertise, and facilitate efficient information sharing and coordination between stakeholders.
Aim 2: To evaluate the impact of the SCD SIMCS on access to screening and care and outcomes of children with SCD (R33 Phase). Hypotheses: The SCD SIMCS will enable universal SCD screening of infants in participating communities, facilitate coordination of their clinical care, and result in reduction of morbidity and mortality due to SCD in participating communities. The investigators will perform a clustered randomized trial (CRT) of the SCD SIMCS among health centers in one urban and three rural districts of Uganda. The goal is to generate community level evidence on the impact of the SCD SIMCS to inform its adoption and expansion to a national scale in Uganda, and adaptation to other LMIC countries.
In Phase 1 the investigators will finalize creation of short videos for patient education, integrate the modules of the SCD SIMCS ≥3G cell phone App and test its integration with the Ministry of Health (MOH) Tier3 data center. The investigators will also optimize the analytics and informatics algorithms for data transmitted to the MOH data center. Reiterations of improvements and testing to optimize the design and functionalities of the App and SCD SIMCS will be made based on user feedback. Phase 1 will be conducted at Mulago National Referral Hospital and, later, piloted in a sample of health centers in the city of Kampala. In Phase 2 the investigators will conduct a Cluster Randomized Trial (CRT) involving health centers in one urban district (Kampala) and three rural districts that have established community research infrastructure; the Iganga-Mayuge Health Demographic Survey Site (IMHDSS) and Rakai Health Research Program (RHRP).
The investigators expect the proposed SCD SIMCS to reduce SCD mortality and morbidity by expanding access to screening, facilitating continuity and coordination of care, and providing real time data for national SCD policy and planning and research. Our team involves stakeholders with the mandate and resources to successfully conduct the proposed research and, most critically, to integrate and sustain the SCD SIMCS in the health system.
- Conditions
- Sickle Cell Disease
- Being tested
- Digital app and information system
- Medical subject headings
- Anemia, Sickle Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Digital app and information systemOther
A custom digital app and information system that consists of four modules: (1) ID module - captures child's demographic and biometric data and builds a printable QR-code; (2) Assay module - captures point of care test image, interprets, and transmits results to the central ministry of health data center; (3) Education module - stores and plays back short educational videos for pre- and post-screening counseling; (4) SCD e-Passport module - entry and display of child's salient clinical information.
| Study group | Role | What they receive |
|---|---|---|
| App/digital system | Experimental | Experimental Hospital/HCs will be provided with point of care test kits and smart phones loaded with airtime credit and the SCD SIMCS app. The health workers that normally provide pediatric care at the facilities will be trained in using the kits and SCD SIMCS app. Outcome measures to compare the effectiveness of SCD screening with and without the SIMCS will include proportions of accurately interpreted assay results, parents that receive counseling, infants seen for SCD care within 1 month of screening, and infants on penicillin. Variables to compute these outcome measures will be entered into cellphone eCRFs (Controls) or automatically transmitted from the SCD SIMCS App (Experimental) and retrieved from the SCD SIMCS database. Chi-squared test and contingent 95% confidence intervals and p-values will be computed to compare the proportions between SIMCS vs. non-SIMCS hospital/HCs. Receives: Other: Digital app and information system |
| No App/digital system | Active comparator | Control Hospital/HCs will be provided with point of care test kits and smart phones loaded with airtime credit BUT no SCD SIMCS app. The health workers that normally provide pediatric care at the facilities will be trained in using the kits. To enable independent verification of the accuracy of interpretation of assay results, health workers will use the smart phones to take and send a photographic caption of every used point of care test strip to a designated central study phone from which they will be downloaded into a computer database. Control infants will be IDed by study number in the SCD SIMCS database. Receives: Other: Digital app and information system |
What is being measured
The primary outcome is the main question the study is designed to answer.
Access to sickle cell disease screening and care
Proportion of infants with sickle cell disease seen at health center within one month of diagnosis
Measured: One month from screening for sickle cell disease
Access to evidence-based care for sickle cell disease
Proportion of children under five that are diagnosed with sickle cell disease and receiving penicillin prophylaxis
Measured: One year from diagnosis of sickle cell disease
Impact of a coordinated screening and treatment program
Adjusted mortality rate for children with sickle cell disease
Measured: Two years from diagnosis of sickle cell disease
Secondary outcomes (3)
Cost of sickle cell disease screening
Financial cost per child screened
Measured: Two years
Access to evidence-based care for sickle cell disease
Proportion of children with sickle cell disease on hydroxyurea therapy
Measured: Two years from diagnosis of sickle cell disease
Impact of a coordinated screening and treatment program
Prevalence of complications of sickle cell disease including erythrocyte transfusion, sepsis, stroke, and growth delay
Measured: Two years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2024
- Study start21 Aug 2024 (estimated)
- Primary completion31 Jul 2027 (estimated)
- Study completion31 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sickle Cell DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Cluster randomized trial
- Masking
- None (open label)
- Enrolment
- 24,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Makerere University
- Sponsor type
- University, hospital or other
- Collaborators
- Baylor College of Medicine, Ministry of Health, Uganda
- Responsible party
- Principal investigator, College of Health Sciences, Makerere University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06563440
- Sponsor's protocol ID
- MakSOMREC-2021-254
- Acronym
- SIMCS SCD
- Status last verified
- Aug 2024
- First submitted
- 19 Aug 2024
- Last updated
- 22 Aug 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Evaluation of an Information Management System and Communication System for Population-wide Point-of-care Infant Sickle Cell Disease Screening
- ClinicalTrials.gov ID
- NCT06563440
- Acronym / sponsor ID
- SIMCS SCD / MakSOMREC-2021-254
- Conditions
- Sickle Cell Disease
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 24,000 participants (estimated)
- Lead sponsor
- Makerere UniversityUniversity, hospital or other
- Collaborators
- Baylor College of Medicine, Ministry of Health, Uganda
- Study start
- 21 Aug 2024 (estimated)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Jul 2028 (estimated)
- First posted
- 20 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Although over 75% of children with sickle cell disease (SCD) are born in sub-Sahara where the disease highly contributes to under-5 mortality and causes life-long debilitation, evidence-based strategies to control SCD are not widely implemented in this region. Early detection of SCD by universal infant screening is a pillar of SCD control. Despite the affordability and move to adopt point-of-care (POC) SCD screening assays in sub-Sahara Africa, the absence of screening information management and communication systems (SIMCS) impedes standardized, systematic, coordinated, nationwide SCD screening programs. The long-term goal of the proposed research is to develop a SCD SIMCS that will enable universal SCD screening in the sub-Sahara African setting. The objective is to test and optimize a custom SCD SIMCS app and digital network to facilitate SCD screening and then evaluate its impact on access to SCD screening and care and on clinical outcomes of children with SCD in Uganda. The central hypothesis is that the SCD SIMCS will facilitate accurate and coordinated POC SCD screening that is accessible at health centers in urban and rural Uganda. The rationale is to build a custom SCD SIMCS on existing nationwide digital and health infrastructure in Uganda to standardize use of affordable POC assays at health centers nationwide. The central hypothesis will be tested by pursuing two specific aims: 1) Develop and evaluate a four-module ≥3G cell phone app for a novel SCD SIMCS (R21 Phase); 2) Evaluate the impact of the SCD SIMCS on access to screening and care and outcomes of children with SCD (R33 Phase). The investigators will pursue these aims using an innovative combination of software design and re-organization of SCD screening workflows. These include assembly of off-the-shelf software that is compatible with iOS and Android operating systems to reliably, accurately, and handily capture, interpret, transmit, and retrieve/playback information for patient's IDs, test results, salient clinical events, and education. The novel screening workflows are expected to dramatically reduce the cost and increase access to SCD screening and care. The proposed research is significant, because it will determine how to use POC SCD screening assays on a large nationwide scale. It will also enable coordination of evidence-based care and continuity of care between primary and specialist providers and longitudinally over the patient's lifetime - a critical aspect in controlling this life-long disease. The SCD SIMCS will also facilitate real time data management for research and policy for SCD control. The expected immediate outcome of this research is a SCD SIMCS that optimally functions on the digital and health infrastructure in Uganda and demonstration of its impact on access to SCD screening and care and on clinical outcomes of children with SCD. The expected long-term outcome is that the SCD SIMCS will be adopted, integrated, and scaled-up in the health systems of Uganda and other sub-Sahara Africa countries, particularly those where the POC assays have already been adopted as the national standard of SCD screening. If effective, the SCD SIMCS will have an important positive impact because it will reduce the cost of SCD screening, take screening services and evidence-based care closer to rural communities where the majority of children in sub-Sahara Africa live, and, ultimately, save millions of children from preventable and disability death.
Detailed description
This trial builds on our multidisciplinary experience in pediatric sickle cell disease (SCD) care, mHealth platforms, and community-based research in Uganda to develop, validate, and trial a novel SCD screening information management and communication system (SCD SIMCS) that enables community-wide point-of-care (POC) SCD screening and care coordination. The SCD SIMCS network will be built on existing population-wide digital infrastructure and a Tier2 data center at the Uganda Ministry of Health (MOH) hub. The network will consist of 3 components: (1) ≥2G cell phone (patients) for short message service (SMS); (2) ≥3G cell phone (providers) for a custom Application (App) that facilitates SCD testing, patient education, and care coordination; (3) Tier2 data center (MOH hub) to receive, curate and transmit data and information in the SCD SIMCS network. The network will involve families, primary care providers (PCP), pediatric hematology specialists, and a national MOH hub for SCD screening. The purpose is to improve outcomes of children with SCD through early detection and linkage into care.
SCD is a group of inherited chronic red blood cell (RBC) disorders characterized by chronic hemolytic anemia, pain crises, and end-organ damage. SCD affects about 15 million individuals in SSA, and about 340,000 children are born with the disease annually. Only 10% of these children reach adolescence in SSA compared to almost 90% of patients that reach adulthood in high-income countries.3 Although SCD contributes about 16% of under-5 mortality in SSA, it is under-recognized because most children die of the disease without a diagnosis.
Early detection through screening is the foremost strategy in reducing SCD morbidity and mortality because it is a pre-requisite for prevention of complications using interventions such as hydroxyurea, vaccination, and health education.24 Whereas several assays for SCD screening exist, attempts to introduce them in SSA at a large scale have been futile because of the unaffordable logistics and complex workflows involved in traditional designs of infant screening programs. Transportation of samples and maintenance of sample-patient ID, transmission of test results to families and providers, pre- and post-screening counseling, referral for treatment for those diagnosed with SCD, and program evaluation are all critical steps in screening and are dependent on affordability, reliability, and integrity of information transfer between the stakeholders at each step. The investigators hypothesize that the SCD SIMCS will bridge these gaps in the screening process in Uganda and sustainably improve outcomes of children with SCD. The investigators propose the following Specific Aims to develop, validate, and trial a sustainable and error-proof mHealth system that will subsequently be adoptable and sustainable to facilitate population-wide SCD screening in Uganda:
Aim 1. To develop and evaluate a four-module ≥3G cell phone app for a novel SCD screening information management and communication system (SIMCS) (R21 Phase). The App will capture and interpret POC assays, capture and maintain a high-fidelity patient ID system, serve as a SCD e-passport interface, and facilitate SCD pre- and post- test counseling. The investigators will iteratively test the feasibility, accuracy, reproducibility, efficacy and robustness of the custom App and SCD SIMCS in our Mulago National Referral Hospital (MNRH)/Makerere University College of Health Sciences (MakCHS) Sickle Cell Program and affiliated primary health centers in Kampala. The goal is to enable a simple, error-free, reliable, and standardized SCD screening using a low-cost POC assay that can be performed across wide ranging health center levels and health worker expertise, and facilitate efficient information sharing and coordination between stakeholders.
Aim 2: To evaluate the impact of the SCD SIMCS on access to screening and care and outcomes of children with SCD (R33 Phase). Hypotheses: The SCD SIMCS will enable universal SCD screening of infants in participating communities, facilitate coordination of their clinical care, and result in reduction of morbidity and mortality due to SCD in participating communities. The investigators will perform a clustered randomized trial (CRT) of the SCD SIMCS among health centers in one urban and three rural districts of Uganda. The goal is to generate community level evidence on the impact of the SCD SIMCS to inform its adoption and expansion to a national scale in Uganda, and adaptation to other LMIC countries.
In Phase 1 the investigators will finalize creation of short videos for patient education, integrate the modules of the SCD SIMCS ≥3G cell phone App and test its integration with the Ministry of Health (MOH) Tier3 data center. The investigators will also optimize the analytics and informatics algorithms for data transmitted to the MOH data center. Reiterations of improvements and testing to optimize the design and functionalities of the App and SCD SIMCS will be made based on user feedback. Phase 1 will be conducted at Mulago National Referral Hospital and, later, piloted in a sample of health centers in the city of Kampala. In Phase 2 the investigators will conduct a Cluster Randomized Trial (CRT) involving health centers in one urban district (Kampala) and three rural districts that have established community research infrastructure; the Iganga-Mayuge Health Demographic Survey Site (IMHDSS) and Rakai Health Research Program (RHRP).
The investigators expect the proposed SCD SIMCS to reduce SCD mortality and morbidity by expanding access to screening, facilitating continuity and coordination of care, and providing real time data for national SCD policy and planning and research. Our team involves stakeholders with the mandate and resources to successfully conduct the proposed research and, most critically, to integrate and sustain the SCD SIMCS in the health system.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Cluster randomized trial
| Arm | Type | Receives |
|---|---|---|
| App/digital system | Experimental | Other: Digital app and information systemExperimental Hospital/HCs will be provided with point of care test kits and smart phones loaded with airtime credit and the SCD SIMCS app. The health workers that normally provide pediatric care at the facilities will be trained in using the kits and SCD SIMCS app. Outcome measures to compare the effectiveness of SCD screening with and without the SIMCS will include proportions of accurately interpreted assay results, parents that receive counseling, infants seen for SCD care within 1 month of screening, and infants on penicillin. Variables to compute these outcome measures will be entered into cellphone eCRFs (Controls) or automatically transmitted from the SCD SIMCS App (Experimental) and retrieved from the SCD SIMCS database. Chi-squared test and contingent 95% confidence intervals and p-values will be computed to compare the proportions between SIMCS vs. non-SIMCS hospital/HCs. |
| No App/digital system | Active comparator | Other: Digital app and information systemControl Hospital/HCs will be provided with point of care test kits and smart phones loaded with airtime credit BUT no SCD SIMCS app. The health workers that normally provide pediatric care at the facilities will be trained in using the kits. To enable independent verification of the accuracy of interpretation of assay results, health workers will use the smart phones to take and send a photographic caption of every used point of care test strip to a designated central study phone from which they will be downloaded into a computer database. Control infants will be IDed by study number in the SCD SIMCS database. |
Who may qualify
- Ages
- Up to 5 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Digital app and information systemA custom digital app and information system that consists of four modules: (1) ID module - captures child's demographic and biometric data and builds a printable QR-code; (2) Assay module - captures point of care test image, interprets, and transmits results to the central ministry of health data center; (3) Education module - stores and plays back short educational videos for pre- and post-screening counseling; (4) SCD e-Passport module - entry and display of child's salient clinical information. | Other | App/digital system, No App/digital system |
Primary outcome
Access to sickle cell disease screening and care
Time frame: One month from screening for sickle cell disease
Proportion of infants with sickle cell disease seen at health center within one month of diagnosis
Access to evidence-based care for sickle cell disease
Time frame: One year from diagnosis of sickle cell disease
Proportion of children under five that are diagnosed with sickle cell disease and receiving penicillin prophylaxis
Impact of a coordinated screening and treatment program
Time frame: Two years from diagnosis of sickle cell disease
Adjusted mortality rate for children with sickle cell disease
3 secondary outcomes
Cost of sickle cell disease screening
Time frame: Two years
Access to evidence-based care for sickle cell disease
Time frame: Two years from diagnosis of sickle cell disease
Impact of a coordinated screening and treatment program
Time frame: Two years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Aug 2024.
- Individual participant dataSharing planned: No
Related trials for Sickle Cell Disease
Active, not recruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Sickle Cell Disease, Hemolytic Anemia
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
RecruitingPhase 1
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Sickle Cell Disorders, Sickle Cell Disease
RecruitingPhase 4
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Not yet recruitingPhase 1
Buprenorphine for the Management of Pain in Children With Sickle Cell Disease
Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Digital app and information system in people with Sickle Cell Disease, run by Makerere University at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States, Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nelson K Sewankambo, MBChB, MMed (+256782366751, sewankam@infocom.co.ug), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Access to sickle cell disease screening and care (time frame: One month from screening for sickle cell disease). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2024.